Strategic partnerships Eisai actively engages in public-private collaborations (eg AHEAD 3-45 with NIH funding, WashU neuroscience collaboration, and BioArctic partnership) which signals openness to co-development and funded research opportunities that sales teams can leverage to propose joint programs, licensing, or access to early-stage assets.

Neurology focus With core emphasis on neurology and dementia-related diseases, Eisai presents ongoing demand for CNS trial support, specialized patient engagement programs, and neurodegenerative therapy commercialization opportunities that align with our portfolio and can drive targeted outreach to neuroscience researchers and clinics.

Expansion potential Recent regional partnerships (Eurofarma in Brazil, US subcutaneous lecanemab-irmb launch) indicate a strategy of geographic expansion and new formulation accessibility, offering opportunities to discuss licensing, distribution, and localized manufacturing or supply chain services.

Integrated capabilities As a fully integrated end-to-end pharma business with discovery, development, and marketing capabilities, Eisai is a cross-sell candidate for consulting, analytics, and technology services that support data-driven decision making across discovery, clinical, and commercial functions.

Data and tech enablement Eisai employs modern data and collaboration tools (Qlik, SAP BO, Apache Airflow, Google Workspace, Microsoft 365, Teams) which suggests opportunities to offer data analytics, workflow automation, and cloud-based productivity enhancements to optimize R&D and commercial operations.